AGL 38.15 Increased By ▲ 0.90 (2.42%)
AIRLINK 121.51 Decreased By ▼ -2.51 (-2.02%)
BOP 5.85 Increased By ▲ 0.23 (4.09%)
CNERGY 3.75 Increased By ▲ 0.03 (0.81%)
DCL 8.40 Increased By ▲ 0.15 (1.82%)
DFML 40.89 Increased By ▲ 0.62 (1.54%)
DGKC 84.60 Decreased By ▼ -1.14 (-1.33%)
FCCL 32.70 Increased By ▲ 0.10 (0.31%)
FFBL 65.50 Decreased By ▼ -1.00 (-1.5%)
FFL 10.05 Decreased By ▼ -0.11 (-1.08%)
HUBC 103.80 Increased By ▲ 0.70 (0.68%)
HUMNL 13.25 Decreased By ▼ -0.15 (-1.12%)
KEL 4.43 Increased By ▲ 0.18 (4.24%)
KOSM 7.09 Decreased By ▼ -0.09 (-1.25%)
MLCF 37.50 Decreased By ▼ -0.80 (-2.09%)
NBP 60.25 Decreased By ▼ -4.76 (-7.32%)
OGDC 172.25 Decreased By ▼ -1.55 (-0.89%)
PAEL 24.80 Decreased By ▼ -0.10 (-0.4%)
PIBTL 5.70 Decreased By ▼ -0.10 (-1.72%)
PPL 141.69 Decreased By ▼ -1.01 (-0.71%)
PRL 22.72 Decreased By ▼ -0.26 (-1.13%)
PTC 14.74 Decreased By ▼ -0.37 (-2.45%)
SEARL 64.56 Decreased By ▼ -0.79 (-1.21%)
TELE 7.14 Increased By ▲ 0.14 (2%)
TOMCL 35.50 Decreased By ▼ -1.41 (-3.82%)
TPLP 7.29 Decreased By ▼ -0.05 (-0.68%)
TREET 14.20 Decreased By ▼ -0.08 (-0.56%)
TRG 51.75 Increased By ▲ 2.05 (4.12%)
UNITY 26.60 Increased By ▲ 0.45 (1.72%)
WTL 1.22 Decreased By ▼ -0.02 (-1.61%)
BR100 9,483 Decreased By -118.3 (-1.23%)
BR30 28,371 Decreased By -202.1 (-0.71%)
KSE100 88,967 Decreased By -1319.8 (-1.46%)
KSE30 27,827 Decreased By -515.9 (-1.82%)

Cancer scientists in Britain are launching what they call the world's first "Darwinian" drug development programme in a bid to get ahead of cancer's ability to become resistant to even the newest treatments and recur in many patients. While not abandoning the search for an ultimate cure, the "anti-evolution" project will re-focus on turning cancer into a disease controllable with drugs for many years.
This would be a little like HIV, the virus that causes AIDS, the scientists told reporters at a briefing. "Cancer's ability to adapt, evolve and become drug-resistant is the cause of the vast majority of deaths from the disease and the biggest challenge we face in overcoming it," said Paul Workman, chief executive of Britain's Institute of Cancer Research (ICR) - a charity and research institute which will lead the new Centre for Cancer Drug Discovery. The centre, funded with 75 million pounds ($96.5 million)from the ICR, will "seek to meet the challenge of cancer evolution head on", Workman said, by blocking its process of evolution.
Teams at the new centre will initially focus on two possible paths to doing this. The first, known as "evolutionary herding", involves selecting an initial specific treatment that forces cancer cells to adapt in a way that makes them highly susceptible to a second drug, or pushes them into an evolutionary dead end. The second will explore a possible new class of drugs to target cancer's ability to evolve and become resistant to treatment. These potential drugs would be designed to block the action of molecules called APOBEC proteins, found in the body's immune system. Researchers hope a new class of APOBEC inhibitors could be developed and given alongside targeted cancer treatments to try and keep cancer at bay for much longer.

Copyright Reuters, 2019

Comments

Comments are closed.